BioAffinity Current Deferred Revenue from 2010 to 2025
BIAF Stock | USD 0.33 0.02 5.71% |
Current Deferred Revenue | First Reported 2010-12-31 | Previous Quarter 24.4 K | Current Value 23 K | Quarterly Volatility 3.2 K |
Check BioAffinity Technologies, financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioAffinity Technologies,'s main balance sheet or income statement drivers, such as Depreciation And Amortization of 635.9 K, Interest Expense of 87.9 K or Gross Profit of 3.5 M, as well as many indicators such as Price To Sales Ratio of 1.12, Dividend Yield of 0.0 or PTB Ratio of 4.45. BioAffinity financial statements analysis is a perfect complement when working with BioAffinity Technologies, Valuation or Volatility modules.
BioAffinity | Current Deferred Revenue | Build AI portfolio with BioAffinity Stock |
Currently Active Assets on Macroaxis
USOI | Credit Suisse X Links | |
ULTY | Tidal Trust II | |
CONY | YieldMax N Option | |
BCAT | BlackRock Capital Allocation | |
PDI | Pimco Dynamic Income |
Check out the analysis of BioAffinity Technologies, Correlation against competitors. For more detail on how to invest in BioAffinity Stock please use our How to Invest in BioAffinity Technologies, guide.You can also try the Balance Of Power module to check stock momentum by analyzing Balance Of Power indicator and other technical ratios.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of BioAffinity Technologies,. If investors know BioAffinity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about BioAffinity Technologies, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (0.71) | Revenue Per Share | Quarterly Revenue Growth (0.23) | Return On Assets | Return On Equity |
The market value of bioAffinity Technologies, is measured differently than its book value, which is the value of BioAffinity that is recorded on the company's balance sheet. Investors also form their own opinion of BioAffinity Technologies,'s value that differs from its market value or its book value, called intrinsic value, which is BioAffinity Technologies,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because BioAffinity Technologies,'s market value can be influenced by many factors that don't directly affect BioAffinity Technologies,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between BioAffinity Technologies,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if BioAffinity Technologies, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, BioAffinity Technologies,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.